These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 25360775)

  • 1. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis.
    Cheng D; Fei Y; Liu Y; Li J; Chen Y; Wang X; Wang N
    PLoS One; 2014; 9(10):e111543. PubMed ID: 25360775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus patients with moderate to severe renal impairment: a meta-analysis.
    Chen Y; Men K; Li XF; Li J; Liu M; Fan ZQ
    Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3502-3514. PubMed ID: 29917205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D; Li L; Liu C
    Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis.
    Chen M; Liu Y; Jin J; He Q
    Ren Fail; 2016; 38(4):581-7. PubMed ID: 26915531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
    BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl Peptidase-4 Inhibitors in Chronic Kidney Disease: A Systematic Review of Randomized Clinical Trials.
    Walker SR; Komenda P; Khojah S; Al-Tuwaijri W; MacDonald K; Hiebert B; Tangri N; Nadurak SWD; Ferguson TW; Rigatto C; Tangri N
    Nephron; 2017; 136(2):85-94. PubMed ID: 28178698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients with moderate to severe chronic kidney disease: Meta-analysis of randomized controlled trials using unadjusted data.
    Yang M; Wang L; Gu L; Yuan W
    J Diabetes; 2017 Dec; 9(12):1107-1117. PubMed ID: 28266136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term and long-term effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta-analysis of randomized controlled trials.
    Li R; Wang R; Li H; Sun S; Zou M; Cheng G
    Diabetes Metab Res Rev; 2016 Sep; 32(6):460-9. PubMed ID: 26433213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
    Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Iacomelli I; Marchionni N; Mannucci E
    Nutr Metab Cardiovasc Dis; 2010 May; 20(4):224-35. PubMed ID: 19515542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis.
    Tricco AC; Antony J; Khan PA; Ghassemi M; Hamid JS; Ashoor H; Blondal E; Soobiah C; Yu CH; Hutton B; Hemmelgarn BR; Moher D; Majumdar SR; Straus SE
    BMJ Open; 2014 Dec; 4(12):e005752. PubMed ID: 25537781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease.
    Mikhail N
    Postgrad Med; 2012 Jul; 124(4):138-44. PubMed ID: 22913902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.
    Rehman MB; Tudrej BV; Soustre J; Buisson M; Archambault P; Pouchain D; Vaillant-Roussel H; Gueyffier F; Faillie JL; Perault-Pochat MC; Cornu C; Boussageon R
    Diabetes Metab; 2017 Feb; 43(1):48-58. PubMed ID: 27745828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.
    Zhang Y; Hong J; Chi J; Gu W; Ning G; Wang W
    Diabetes Metab Res Rev; 2014 Mar; 30(3):241-56. PubMed ID: 24123720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
    Stoimenis D; Karagiannis T; Katsoula A; Athanasiadou E; Kazakos K; Bekiari E; Matthews DR; Tsapas A
    Expert Opin Pharmacother; 2017 Jun; 18(9):843-851. PubMed ID: 28448177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
    Richard KR; Shelburne JS; Kirk JK
    Clin Ther; 2011 Nov; 33(11):1609-29. PubMed ID: 22071236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Kidney Transplant Recipients with Post-transplant Diabetes Mellitus (PTDM)- a Systematic Review and Meta-Analysis.
    Abdelaziz TS; Ali AY; Fatthy M
    Curr Diabetes Rev; 2020; 16(6):580-585. PubMed ID: 30907326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials.
    Tran S; Retnakaran R; Zinman B; Kramer CK
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():68-76. PubMed ID: 29364587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.